2412.03(e) âModified Nucleotideâ [R-07.2022]
2412.03(e) “Modified Nucleotide” [R-07.2022]
[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]
37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.
-
*****
- (i) “Modified nucleotide” includes any nucleotide as described in paragraph 3(f) of WIPO Standard ST.26.
-
*****
WIPO Standard ST.26, paragraph 3(f), identifies that a “modified nucleotide” means any “nucleotide” as explained in MPEP § 2412.03(d) other than deoxyadenosine 3’-monophosphate, deoxyguanosine 3’-monophosphate, deoxycytidine 3’-monophosphate, deoxythymidine 3’-monophosphate, adenosine 3’-monophosphate, guanosine 3’-monophosphate, cytidine 3’-monophosphate, or uridine 3’-monophosphate.